Hogan Lovells has advised on the sale of Maxinutrition Holdings to Glaxo Group, a subsidiary of GlaxoSmithKline, for GBP162m.
The deal was announced on 13 December and is subject to competition clearance.
Maxinutrition is a European sports nutrition company. Hogan Lovells acted for Zef Eisenberg and Paul Hick, the founder and the former chairman of the business respectively, who both retained stakes in the business when it was sold to Darwin Private Equity in December 2007.
Hogan Lovells also acted on the original Darwin MBO, advising previous owners Piper Private Equity and the selling shareholder group on the sale of the business.
Amit Nayyar, partner in Hogan Lovells’ private equity team, says: "We are pleased to have, once again, advised Maxinutrition on a strategically important transaction. It has been a pleasure to extend our working relationship with the company in what marks the third successful exit for the Maximuscle brand."
Macfarlanes acted for Darwin Private Equity and Slaughter & May acted for Glaxo Group.
